RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma

Molecular Cancer Research

Volumn 13, Issue 1, 2015, Pages 130-137

  Pal, Sumanta K ^a   He, Miaoling ^a   Tong, Tommy ^a   Wu, Huiqing ^a   Liu, Xueli ^a   Lau, Clayton ^a   Wang, Jin Hui ^a   Warden, Charles ^a   Wu, Xiwei ^a   Signoretti, Sabina ^b   Choueiri, Toni K ^b   Karam, Jose A ^c   Jones, Jeremy O ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; AURORA B KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; S6 KINASE; AURKA PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; RNA; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CELL CYCLE M PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE ONTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RENAL CANCER CELL LINE; RNA ANALYSIS; RNA SEQUENCE; SARCOMATOID METASTATIC RENAL CELL CARCINOMA; SIGNAL TRANSDUCTION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AURORA KINASE A; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RNA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84921776079     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0352     Document Type: Article

References (49)

1. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22:4991-5004.
2. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 2012;11:526-37.
3. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, et al. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int 2012;109:1600-6.
4. Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist 2012;17:46-54.
5. Pal SK, Jones JO, Carmichael C, Saikia J,Hsu J, Liu X, et al. Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis. Urol Oncol 2013;31:1826-31.
6. Golshayan AR, George S, Heng DY, Elson P,Wood LS,Mekhail TM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009;27:235-41.
7. Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, et al. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol 2014;25:663-8.
8. Shuch B, Said J, La Rochelle JC, Zhou Y, Li G, Klatte T, et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology-is up-front resection indicated and, if not, is it avoidable? J Urol 2009;182:2164-71.
9. Motzer RJ, Bacik J, MazumdarM. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004;10:6302S-6303S.
10. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40.
11. Crane R, Kloepfer A, Ruderman JV. Requirements for the destruction of human Aurora-A. J Cell Sci 2004;117:5975-83.
12. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-48.
13. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72.
14. Song J, Salek-Ardakani S, So T, Croft M. The kinases aurora B and mTOR regulate the G1-S cell cycle progression of T lymphocytes. Nat Immunol 2007;8:64-73.
15. Taga M, Hirooka E, Ouchi T. Essential roles of mTOR/Akt pathway in Aurora-A cell transformation. Int J Biol Sci 2009;5:444-50.
16. Pal SK, Quinn DI.Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 2013;39:709-19.
17. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67.
18. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
19. Weng QP, Kozlowski M, Belham C, Zhang A, Comb MJ, Avruch J. Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem 1998;273:16621-9.
20. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
21. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, et al. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 2004;279:22267-75.
22. Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004;23:4624-35.
23. Li Y, Zhou W, Wei L, Jin J, Tang K, Li C, et al. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma. Int J Oncol 2012;41:2139-49.
24. Kuroiwa K, Konomoto T, Kumazawa J, Naito S, Tsuneyoshi M. Cell proliferative activity and expression of cell-cell adhesion factors (E-cadherin, alpha-, beta-, and gamma-catenin, and p120) in sarcomatoid renal cell carcinoma. J Surg Oncol 2001;77:123-31.
25. Conant JL, Peng Z, Evans MF, Naud S, Cooper K. Sarcomatoid renal cell carcinoma is an example of epithelial-mesenchymal transition. J Clin Pathol 2011;64:1088-92.
26. Cates JM, Dupont WD, Barnes JW, Edmunds HS, Fasig JH, Olson SJ, et al. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. Appl Immunohistochem Mol Morphol 2008;16:251-62.
27. Jones TD, Eble JN, Wang M, Maclennan GT, Jain S, Cheng L. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer 2005;104:1195-203.
28. Leroy X, Wacrenier A, De la Taille A, Gosset P, Saint F, Biserte J, et al. Immunohistochemical detection of Fas and Fas ligand in sarcomatoid renal cell carcinoma. APMIS 2001;109:469-73.
29. Castillo M, Petit A, Mellado B, Palacin A, Alcover JB, Mallofre C. C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol 2004;171:2176-80.
30. Sengupta S, Cheville JC, Corless CL, Lohse CM, Heinrich MC, Kwon ED, et al. Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J Urol 2006;175:53-6.
31. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 2012;30:2411-32.
32. Li Y, Zhang ZF, Chen J, Huang D, Ding Y, Tan MH, et al. VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2010;2:296-308.
33. Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 2002;277:20104-12.
34. Figlin RA, Seligson D, Wu H, Thomas G, Leppert JT, O'Toole T, et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. ASCO Meeting Abstracts 2005;23:4539.
35. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177:346-52.
36. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360-3.
37. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-42.
38. Kucejova B, Pena-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 2011;9:1255-65.
39. Shoshani T, Faerman A, Mett I, Zelin E, Tenne T, Gorodin S, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002;22:2283-93.
40. Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008;14:4726-34.
41. Xu J, Li H, Wang B, Xu Y, Yang J, Zhang X, et al. VHL inactivation induces HEF1 and Aurora kinase A. J Am Soc Nephrol 2010;21:2041-6.
42. Klein A, Flugel D, Kietzmann T. Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1. Mol Biol Cell 2008;19:3667-75.
43. Kurahashi T, Miyake H, Hara I, Fujisawa M. Significance of Aurora-A expression in renal cell carcinoma. Urol Oncol 2007;25:128-33.
44. Kikuno N, Kennoki T, Fukuda H, Matsumoto Y, Tsunoyama K, Ban S, et al. Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus. Anticancer Res 2012;32:3443-7.
45. Areses MC, Herranz UA, Ferran BB, Mateos LL, Gonzalez JG, Lopez RL. Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases. Med Oncol 2012;29:795-8.
46. Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, et al. Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium. Cancer Invest 2013;31:323-9.
47. Négrier S, Gravis G, Pérol D, Chevreau C, Delva R, Bay J-O, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12:673-80.
48. Ravaud A, Barrios C, Anak € O, Pelov D, Louveau A, Alekseev B, et al. Randomized phase II study of first-line everolimus (EVE) + bevacizumab (BEV) versus interferon alfa-2a (IFN) + BEV in patients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2. Ann Oncol 2012;23[Abstr 7830].
49. Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer A, Escudier B. Randomized phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. Ann Oncol 2012;23 [Abstr LBA21-PR].